Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,813	$ 20,272	$ 38,606	$ 22,207
Collaborative Revenue
Disaggregation of Revenue [Line Items]
Total revenue	7,443		15,446	706
License and Milestone Fees
Disaggregation of Revenue [Line Items]
Total revenue		20,031	15,000	21,223
Commercial Supply Revenue
Disaggregation of Revenue [Line Items]
Total revenue	3,370		8,160
Clinical Compound Revenue
Disaggregation of Revenue [Line Items]
Total revenue		241		278
Vifor [Member] | License and Milestone Fees
Disaggregation of Revenue [Line Items]
Total revenue		20,031	15,000	20,031
Vifor [Member] | Commercial Supply Revenue
Disaggregation of Revenue [Line Items]
Total revenue	3,370		8,160
Vifor [Member] | Clinical Compound Revenue
Disaggregation of Revenue [Line Items]
Total revenue		241		241
Vifor Profit Sharing [Member] | Collaborative Revenue
Disaggregation of Revenue [Line Items]
Total revenue	7,443		15,446
Maruishi Agreement [Member] | Collaborative Revenue
Disaggregation of Revenue [Line Items]
Total revenue	0	0	0	706
Maruishi Agreement [Member] | License and Milestone Fees
Disaggregation of Revenue [Line Items]
Total revenue	$ 0	$ 0	$ 0	1,192
Maruishi Agreement [Member] | Clinical Compound Revenue
Disaggregation of Revenue [Line Items]
Total revenue				$ 37